PD L1 News and Research

RSS

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.

22 Sep 2021

Specially designed lipid nanoparticles overcome resistance to anti-tumor immunotherapy

A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.

18 Sep 2021

Scientists identify new approach to overcome resistance to cancer immunotherapy

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to immunotherapy treatment for cancer. The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.

17 Sep 2021

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

A synthetic molecular code shows promise towards improving the response of some cancer patients to immunotherapy treatments.

14 Sep 2021

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

Oncotarget published "Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase" which reported that it is necessary to investigate actionable genes and candidate drugs using a sophisticated knowledgebase and characterize BTCs immunologically for evaluating the actionability of molecular and immune therapies.

31 Aug 2021

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.

25 Aug 2021

New PULSAR radiation-therapy strategy achieves better tumor control

Artificial intelligence, along with a $71-million expansion of Radiation Oncology services, is allowing UT Southwestern Medical Center cancer physicians to pioneer a new PULSAR radiation-therapy strategy that improves tumor control compared with traditional daily therapy.

From Elekta 20 Aug 2021

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small cell lung cancer, or NSCLC.

20 Aug 2021

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as patients naïve to these treatments.

19 Aug 2021

Nanotechnology may help improve treatment for colorectal cancer and melanoma

University of Arizona Health Sciences researchers recently completed a study that has the potential to improve cancer treatment for colorectal cancer and melanoma by using nanotechnology to deliver chemotherapy in a way that makes it more effective against aggressive tumors.

12 Aug 2021

New immunotherapy strategy can eliminate pancreatic tumors in mice

Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.

6 Aug 2021

Using circulating tumor DNA to detect urothelial cancer relapse could help improve treatment

Using circulating tumor DNA to identify patients at risk of urothelial cancer relapse after surgical resection could help improve post-surgery treatment.

6 Aug 2021

Researchers develop the most comprehensive molecular map of lung squamous cell carcinoma

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.

5 Aug 2021

Study examines the role of programmed cell death ligands in skin immune responses

T cells are a crucial part of the human adaptive immune system. In response to a foreign invader in the body, various subsets of T cells are responsible for several functions that include killing infected cells and secreting signaling molecules called cytokines that tell other immune cells where to go and what to do.

29 Jul 2021

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Jul 2021

Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer

A research team led by Fumito Ito, MD, PhD, FACS, of Roswell Park Comprehensive Cancer Center reports new data on the promise of combining standard treatment for breast cancer with a particular form of cancer immmunotherapy - dendritic-cell (DC) treatment vaccines.

20 Jul 2021

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

14 Jul 2021

PD L1 News and Research

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Specially designed lipid nanoparticles overcome resistance to anti-tumor immunotherapy

Scientists identify new approach to overcome resistance to cancer immunotherapy

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

New PULSAR radiation-therapy strategy achieves better tumor control

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Nanotechnology may help improve treatment for colorectal cancer and melanoma

New immunotherapy strategy can eliminate pancreatic tumors in mice

Using circulating tumor DNA to detect urothelial cancer relapse could help improve treatment

Researchers develop the most comprehensive molecular map of lung squamous cell carcinoma

Study examines the role of programmed cell death ligands in skin immune responses

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Scientists discover potential marker for the success of immunotherapy in lung cancer patients

Lung cancer patients should be screened for MET oncogene amplification, research suggests

AMSBIO offers an extensive collection of normal and disease state FFPE tissue blocks

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News